Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company targeting acquisition opportunities in the domestic pharmaceutical and life sciences manufacturing sector. The company filed a Form 10-Q with the Securities and Exchange Commission on November 18, 2025, its most recent quarterly disclosure, indicating it remains an active reporting entity as it pursues a business combination. The SPAC's stated sector focus centers on companies involved in domestic drug production and related pharmaceutical operations within the United States. Sponsor details and IPO-vintage data are available to subscribers. For the complete filing history, deal-stage tracking, and sponsor intelligence on DMAA and thousands of other SPACs, sign up for full access at SpacDesk.